TY - CHAP M1 - Book, Section TI - Testicular Cancer A1 - Feldman, Darren R. A1 - Bosl, George J. A2 - Boyiadzis, Michael M. A2 - Frame, James N. A2 - Kohler, David R. A2 - Fojo, Tito PY - 2016 T2 - Hematology-Oncology Therapy, 2e AB - EpidemiologyTable Graphic Jump Location|Download (.pdf)|PrintIncidence:8,820 estimated new cases for 2014 in the United States5.5 per 100,000 males per yearDeaths:Estimated 380 in 2014Median age:33 yearsSiegel R et al. CA Cancer J Clin 2013;63:11–30Surveillance, Epidemiology and End Results (SEER) Program, available from http://seer.cancer.gov (accessed in 2013)Table Graphic Jump Location|Download (.pdf)|PrintEpidemiologyFrequency of Stage at Presentation SeminomaNonseminomaStage I85%60%Stage II10%20%Stage III5%20%Frequency of IGCCCG Risk Groups at Diagnosis for Patients Requiring ChemotherapyIGCCCG Risk GroupSeminomaNonseminomaAllGood90%56%60%Intermediate10%28%26%PoorN/A16%14%IGCCCG, International Germ Cell Cancer Collaborative Group; GCT germ cell tumorBiggs M, Schwartz S. “Cancer of the Testis.” In Ries SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988–2001. 2007:165–170Bosl G et al. In Devita V, Lawrence T, Rosenberg S, eds. Cancer: Principles and Practice of Oncology. Philadelphia: Lippincott Williams and Wilkins, 2008:1463–1485International Germ Cell Cancer Collaborative Group (IGCCCG). J Clin Oncol 1997;15:594–603Siegel R et al. CA Cancer J Clin 2014;64:9–29 SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/03/29 UR - hemonc.mhmedical.com/content.aspx?aid=1128366747 ER -